Home » Newsletters » BioWorld

BioWorld

Aug. 26, 1992

View Archived Issues

ZYNAXIS SBIR TO MEASURE LDL CONCENTRATIONS

APPOINTMENTS AND ADVANCEMENTS

SCIGENICS STOCK FALLS FOR SECOND STRAIGHT DAY

ONCOR CONTINUES PACT FOR DNA PROBES

REGENERON'S STOCK FALLS ON RIVAL'S PATENT

MEDIZONE, INVESTORS REACH AGREEMENT

MERIDIAN GETS FDA OK FOR HISTOPLASMOSIS ENZYME

BIOCHEM PHARMA, BRI IN RESEARCH PACT

CYTOGEN, CHIRON EXPAND ONCOSCINT MARKETING IN EUROPE

ABBOTT FILES NDA FOR BIAXIN

FDA DELAY PULLS ALTEON DOWN $2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.